LOL,
@bulkbiker! I read this study a couple of weeks ago and was tempted to share then but it was like a Russian novel - I needed to write down a glossary of abbreviations just to keep them all straight as I read! My head was spinning! Anyway I did take notes with an intent to share and this is my takeaway:
The overarching message is that this new classification (if generalisable to other ethnic groups) will enable health systems to tailor treatment and/or screening to the underlying metabolic defect or complication associated with a particular cluster. So, think more 'precision medicine' than 'one size fits all'.
They identified 2 new, more severe forms of diabetes previously masked within T2DM:
Clusters 2 & 3.
Cluster 2: Associated with a higher risk of Diabetic Retinopathy:
In terms of screening for complications, individuals with Cluster 2 may be best served by receiving more intensive screening for diabetic retinopathy, while those in Cluster 5 (for example) may only need to be screened every 2 years (again, using scarce healthcare funds wisely to have maximum benefit for the most people).
Cluster 3: Associated with a higher risk of Diabetic Kidney Disease (DKD):
Similarly, those in Cluster 3 warrant very close observation/screening for development of chronic kidney disease, as
this cluster had 5 times the risk of developing End Stage Renal Disease than Cluster 5. This would also have implications for prescribing certain medications: for example Metformin should perhaps be used with caution in this group.
The big takeaway with Cluster 3 was that their marked increase in Diabetic Kidney Disease was seen
'in spite of a relatively low HbA1c, suggesting that glucose-lowering therapy is not the ultimate way of preventing DKD'.
The study looked at the following 5 quantifiable variables, and they suggest that following these 5 variables is superior to measuring glucose alone:
- Age
- BMI
- HOMA 2-IR
- Presence or absence of GAD antibodies
- Fasting glucose and C-Peptide to estimate HOMA 2.
They also looked at genetic markers but noted that their stratification could be further refined by including additional genetic 'biomarkers, genotypes or genetic risk scores'.